Related Experiment Video
Updated: Apr 29, 2026
Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface
Published on: February 21, 2011
Mitsugumin 53 protects against smoke inhalation lung injury via suppressing the proinflammatory response in a rat
Daniel Z Aziz1, C Chase Binion2, Xiaoliang Wang1
1University of Virginia, Department of Surgery, Charlottesville, VA, USA.
Objectives:
This study investigates the therapeutic potential of recombinant human Mitsugumin 53 (rhMG53) in a rodent model of smoke-induced acute lung injury (SI-ALI). We hypothesize that administration of rhMG53 will improve pulmonary function and attenuate inflammation following SI-ALI.
Methods:
Sprague Dawley rats (n = 6-9/group, 300-400 g) underwent smoke inhalation or sham. Smoke-exposed rats received intravenous rhMG53 or saline. Arterial blood gases were obtained at baseline and 2, 6, and 24 h post smoke inhalation. Lung tissue collected at 24 h was analyzed via histopathology, immunofluorescence, bulk RNA sequencing, quantitative PCR, and western blotting.
Results:
Six hours after smoke exposure, saline-treated rats exhibited dampened partial pressure of oxygen, whereas the rhMG53 group showed significant improvement (62.67 ± 15.81 vs. 75.83 ± 12.16 mmHg, P < .01). By 24 h, saline-treated animals remained significantly hypoxemic (79.33 mmHg, P < .01 vs. baseline), while rhMG53-treated rats recovered to baseline (87.17 mmHg), trending toward significantly higher oxygenation versus saline (P = 0.0503). Smoke-exposed saline-treated rats exhibited increased overall histopathological scores, which were reduced with rhMG53 (0.60 ± 0.17 vs. 0.37 ± 0.05, P < .01). Gene ontology analysis revealed rhMG53 mitigated smoke-induced upregulation of inflammatory response pathways. Induction of pro-inflammatory genes and elevation of NLRP3 inflammasome expression observed in smoke-exposed saline-treated lungs was significantly suppressed by rhMG53, as corroborated by qPCR and western blotting.
Conclusions:
This study provides preclinical evidence for rhMG53 as a potential therapeutic for SI-ALI. RhMG53 improved oxygenation, reduced neutrophilic inflammation, and suppressed NLRP3 inflammasome activation. Further investigations in diverse models of ALI are warranted to define the therapeutic scope and translational potential of rhMG53.
Insights
Recombinant human Mitsugumin 53 (rhMG53) therapy improved oxygenation and reduced inflammation in a rodent model of smoke-induced acute lung injury (SI-ALI). This suggests rhMG53 is a promising treatment for SI-ALI.
Area of Science:
- Pulmonary Medicine
- Regenerative Medicine
- Biochemistry
Background:
- Smoke-induced acute lung injury (SI-ALI) is a significant cause of respiratory distress.
- Current treatments for SI-ALI are limited, necessitating novel therapeutic approaches.
- Recombinant human Mitsugumin 53 (rhMG53) is a protein with potential tissue-repairing properties.
Purpose of the Study:
- To investigate the therapeutic efficacy of rhMG53 in a rodent model of SI-ALI.
- To determine if rhMG53 administration can improve pulmonary function and reduce inflammation post-SI-ALI.
Main Methods:
- Sprague Dawley rats were subjected to smoke inhalation or sham procedures.
- Smoke-exposed rats received intravenous rhMG53 or saline treatment.
- Pulmonary function, blood gases, and lung tissue analyses (histopathology, gene expression, protein levels) were performed.
Main Results:
- rhMG53 treatment significantly improved partial pressure of oxygen levels at 6 and 24 hours post-SI-ALI compared to saline.
- Histopathological scores were reduced in rhMG53-treated rats, indicating less lung damage.
- rhMG53 suppressed smoke-induced upregulation of inflammatory response pathways and NLRP3 inflammasome activation.
Conclusions:
- Preclinical data support rhMG53 as a potential therapeutic agent for SI-ALI.
- rhMG53 demonstrated benefits in improving oxygenation, reducing neutrophilic inflammation, and suppressing NLRP3 inflammasome activation.
- Further research is warranted to explore rhMG53's therapeutic scope in various ALI models.
